# Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine

> **NCT06485752** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Novavax**

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** tNIV 1 and Matrix-M Adjuvant

## Key facts

- **NCT ID:** NCT06485752
- **Lead sponsor:** Novavax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-11
- **Primary completion:** 2025-02-04
- **Final completion:** 2025-02-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Decided to not move forward with the study
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06485752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06485752, "Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06485752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*